Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nautilus Biotechnology (NAUT) Preferred Stock Liabilities (2020 - 2021)

Nautilus Biotechnology has reported Preferred Stock Liabilities over the past 2 years, most recently at $27.1 million for Q1 2021.

  • Quarterly results put Preferred Stock Liabilities at $27.1 million for Q1 2021, changed N/A from a year ago — trailing twelve months through Mar 2021 was $27.1 million (changed N/A YoY), and the annual figure for FY2020 was $75.9 million, changed.
  • Preferred Stock Liabilities reached $27.1 million in Q1 2021 per NAUT's latest filing, down from $75.9 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $75.9 million in Q4 2020 and bottomed at $5.5 million in Q3 2020.